ELEDON PHARMACEUTICALS INC
ELDNNASDAQ🏆 #2629 by market capEarnings Nov 12US Equity
$678.47▼ $47.90 (−7.06%)
Simulated price1h—
24h▼ 7.1%
7d▲ 19680.5%
14d▲ 20428.6%
30d▲ 17499.7%
1y▲ 25454.4%
🏦Market Cap
$284M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
43
Weak
Trading Snapshot
- Day Range
- $669.80 – $685.56
- 52-Week Range
- $1.35 – $4.60
- Volume
- $2.95B
- Avg Volume
- $3.35B
- Shares Outstanding
- 77.2M
- Next Earnings
- Aug 31, 2026
Fundamentals Snapshot
- Annual Revenue
- $28M
- Last Q Revenue
- $7M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-0.83
- Dividend Yield
- —
Why Investors Own ELDN
- ✓High-growth profile — revenue up +22.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 41% gross margin and 10% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$28M▲ +27.5% YoY
Gross Margin (TTM)
41.0%▼ −0.5% YoY
Operating Income (TTM)
$4M▲ +27.5% YoY
Free Cash Flow (TTM)
$3M▲ +27.5% YoY
About ELEDON PHARMACEUTICALS INC
A company profile for ELEDON PHARMACEUTICALS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
43/100
Analyst Price Target
ⓘAverage Target
$733.50
▲ +8.1% Upside
High Target$888.87
Low Target$623.11
Based on 27 analysts
Latest News & Updates
🚀
MarketWatch·2h ago
ELEDON PHARMACEUTICALS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
MarketWatch·5h ago
Analysts lift ELDN price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
CNBC·1d ago
ELEDON PHARMACEUTICALS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.